Market Exclusive

Recro Pharma, Inc. (NASDAQ:REPH) Files An 8-K Other Events

Recro Pharma, Inc. (NASDAQ:REPH) Files An 8-K Other Events

Item8.01

Other Events.

On June8, 2017, Recro Pharma, Inc. (the Company) updated its
corporate presentation, which is attached as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by
reference. Representatives of the Company will use the updated
presentation in various meetings with investors from time to
time.

Item9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.

Document

99.1 Investor presentation of Recro Pharma, Inc.

About Recro Pharma, Inc. (NASDAQ:REPH)
Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.

Exit mobile version